Results 121 to 130 of about 10,402 (207)

Association of Pegylated Liposomal Doxorubicin with Improved Overall Survival Compared with Epirubicin in Early-Stage Breast Cancer: A Population Based Study from Taiwan. [PDF]

Breast Cancer (Dove Med Press)
Chen YC, Cheng MC, Chen PH, Chung CH, Chien WC, Dai MS, Chen JH, Huang TC.   +7 more
europepmc   +1 more source

Cardiac Safety of Pegylated Liposomal Doxorubicin After Conventional Doxorubicin Exposure in Patients With Sarcoma and Breast Cancer. [PDF]

Cureus, 2023
Alhaja M, Chen S, Chin AC, Schulte B, Legasto CS.   +4 more
europepmc   +1 more source

Dexrazoxane Protects Against Hand-Foot Syndrome-Like Skin Damage in Pegylated Liposomal Doxorubicin-Treated Mice. [PDF]

J Toxicol
Nishida K, Tanaka J, Hashimoto C, Tanaka M, Kuga T, Shigeta S, Kitatani K.   +6 more
europepmc   +1 more source

Adjuvant pegylated liposomal doxorubicin versus epirubicin sequential paclitaxel in triple-negative breast cancer: comparable efficacy with a distinct safety profile. [PDF]

Front Immunol
Cai S, Yu S, Lin X, Zhou Q, Zheng X, Chen H, Ma T, Chen X, Sun H, Shi Y.   +9 more
europepmc   +1 more source

The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity. [PDF]

IET Nanobiotechnol, 2022
Dadpour S, Mehrabian A, Arabsalmani M, Mirhadi E, Askarizadeh A, Mashreghi M, Jaafari MR.   +6 more
europepmc   +1 more source

Hypersensitivity Pneumonitis-Like Drug-Induced Interstitial Lung Disease Caused by Pegylated Liposomal Doxorubicin: A Case Report. [PDF]

Cureus
Araya T, Kita T, Higashi T, Hara R, Takato H.   +4 more
europepmc   +1 more source

Phase I Trial of Pegylated Liposomal Doxorubicin Combined with Ifosfamide for Advanced Soft Tissue Sarcoma. [PDF]

Drug Des Devel Ther
Ye T, Fan L, Cao R, Peng L, Chen J.
europepmc   +1 more source

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum-refractory/resistant ovarian cancer. [PDF]

Cancer Med, 2023
Yoshida H, Fujiwara K.
europepmc   +1 more source

Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients

, 2008
Purpose: While most patients with ovarian cancer respond to first-line treatment, 50-75% of these patients will eventually relapse. Pegylated liposomal doxorubicin (PLD) is an active agent indicated for the treatment of patients with disease that is ...
Dikmen Y., Akman L., Karaca B., Uslu R., Cosan-Terek M., Kemal-Gul M., Karabulut B., Kucukzeybek Y., Ozsaran A., Gorumlu G., Sanli U.A.   +10 more
core  

Pegylated liposomal doxorubicin plus carboplatin versus paclitaxel plus carboplatin as first-line therapy for epithelial ovarian cancer (CGCS-04): a multicenter, randomized clinical trial. [PDF]

Ther Adv Med Oncol
Shen Y, Tu N, Kong B, Xia B, Zou Y, Yin R, Li Q, Yue Y, Kang S, Wang K, He L, Wang S, Meng Y, Qu P, Huang X, Guo R, Yan P, Pan M, Cheng W, Lou G, Wang Z.   +20 more
europepmc   +1 more source